Compare JRVR & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRVR | PYXS |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.7M | 243.5M |
| IPO Year | 2005 | 2021 |
| Metric | JRVR | PYXS |
|---|---|---|
| Price | $5.85 | $4.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.06 | ★ $7.00 |
| AVG Volume (30 Days) | 213.9K | ★ 793.2K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $646,580,000.00 | $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $0.83 |
| 52 Week High | $6.27 | $5.55 |
| Indicator | JRVR | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 53.01 |
| Support Level | $5.69 | $3.67 |
| Resistance Level | $5.95 | $5.55 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 71.93 | 44.68 |
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.